GlassScriptPhysician profile
Chona B Green
NPI 1437219441
$9,595.80
in general payments reported to CMS, 2019-2025
29 companies · $1,731 in 2025
The $1,731 reported for 2025 was more than what 88% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,528 · 2020: $1,280 · 2021: $1,615 · 2022: $1,172 · 2023: $1,407 · 2024: $862 · 2025: $1,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,985 · Education: $15.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,984.76 |
| Education | $15.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,082.26 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $1,061.53 | 2019-2025 | Trintellix |
| Abbvie INC. | $1,026.24 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,024.84 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $820.32 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $668.60 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $577.22 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $507.90 | 2019-2025 | Rexulti, Brintellix |
| Allergan, INC. | $497.26 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $488.77 | 2019-2025 | Spravato |
| Axsome Therapeutics, INC. | $348.42 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $206.58 | 2019-2025 | Ingrezza |
| Adlon Therapeutics L.P. | $193.50 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $179.45 | 2023-2025 | Quviviq, Quviviq |
| Tris Pharma INC | $176.98 | 2023 | Dyanavel Xr, Quillichew Er, Quillivant |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $157.51 | 2021-2025 | Loreev Xr |
| Eisai INC. | $110.44 | 2020-2022 | |
| Bausch Health US, LLC | $82.33 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $68.39 | 2025 | |
| Jazz Pharmaceuticals INC. | $58.79 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $44.82 | 2019-2022 | |
| Alfasigma USA, INC. | $40.29 | 2021-2022 | |
| Corium, LLC | $37.84 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.92 | 2025 | Cobenfy |
| Sage Therapeutics, LLC | $26.00 | 2022 | |
| Livanova USA, INC. | $21.39 | 2021 | |
| Owp Pharmaceuticals, INC. | $20.82 | 2023 | Lamotrigine, Subvenite |
| Indivior INC. | $20.20 | 2019 | |
| Sun Pharmaceutical Industries INC. | $18.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chona Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.